Glasdegib with Low-Dose Cytarabine - A New Upfront Option for the Vulnerable AML Patient

Title
Glasdegib with Low-Dose Cytarabine - A New Upfront Option for the Vulnerable AML Patient
Authors
Keywords
-
Journal
CLINICAL CANCER RESEARCH
Volume -, Issue -, Pages clincanres.1986.2019
Publisher
American Association for Cancer Research (AACR)
Online
2019-07-20
DOI
10.1158/1078-0432.ccr-19-1986

Ask authors/readers for more resources

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now